Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, January 1998, p. 164-169, Vol. 42, No. 1
Wellcome Trust Research
Laboratories,1
Kenya Medical Research
Institute,2 and
Department of
Pharmaceutics and Pharmacy Practice, Faculty of Pharmacy, University of
Nairobi,4 Nairobi, Kenya;
University of
Washington Department of Genetics, Seattle, Washington
98195-73603;
University of Maryland,
Division of Geographic Medicine and Entomology, Baltimore, Maryland
212015; and
University of Liverpool,
Department of Pharmacology and Therapeutics, Liverpool L69 3BX,
United Kingdom6
Received 11 June 1997/Returned for modification 20 August
1997/Accepted 20 October 1997
Sixty-nine Kenyan Plasmodium falciparum field isolates
were tested in vitro against pyrimethamine (PM), chlorcycloguanil
(CCG), sulfadoxine (SD), and dapsone (DDS), and their dihydrofolate
reductase (DHFR) genotypes were determined. The in vitro data show that CCG is more potent than PM and that DDS is more potent than SD. DHFR
genotype is correlated with PM and CCG drug response. Isolates can be
classified into three distinct groups based on their 50% inhibitory
concentrations (IC50s) for PM and CCG (P < 0.01) and their DHFR genotypes. The first group consists of
wild-type isolates with mean PM and CCG IC50s of 3.71 ± 6.94 and 0.24 ± 0.21 nM, respectively. The second group
includes parasites which all have mutations at codon 108 alone or also
at codons 51 or 59 and represents one homogeneous group for which 25- and 6-fold increases in PM and CCG IC50s, respectively, are
observed. Parasites with mutations at codons 108, 51, and 59 (triple
mutants) form a third distinct group for which nine- and eightfold
increases in IC50s, respectively, of PM and CCG compared to
the second group are observed. Surprisingly, there is a significant
decrease (P < 0.01) of SD and DDS susceptibility in
these triple mutants. Our data show that more than 92% of Kenyan field
isolates have undergone at least one point mutation associated with a
decrease in PM activity. These findings are of great concern because
they may indicate imminent PM-SD failure, and there is no affordable
antimalarial drug to replace PM-SD (Fansidar).
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Kenyan Plasmodium falciparum Field
Isolates: Correlation between Pyrimethamine and Chlorcycloguanil
Activity In Vitro and Point Mutations in the Dihydrofolate
Reductase Domain
*
Corresponding author. Mailing address: Wellcome Trust
Research Laboratories, P.O. Box 43640, Nairobi, Kenya. Phone: 254 2 725 390 or 254 2 725 398. Fax: 254 2 711 673. E-mail:
wellcome{at}users.africaonline.co.ke.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |